Page 2 - Dr Reddys

Dr Reddy's Q2 preview: Profit may moderate as US sales dip; check estimates

Dr Reddy's net profit is expected to come at ₹1,479 crore, marking a moderate 5.5 per cent Y-o-Y increase, on average, as against ₹1,401 crore in the year-ago period

Dr Reddy's, Zydus recall products in US over manufacturing issues: USFDA

Drug majors Dr Reddy's Laboratories and Zydus Lifesciences are recalling products in the US for manufacturing issues, according to the US health regulator. In its latest Enforcement Report, US Food and Drug Administration (USFDA) stated that an American subsidiary of the Hyderabad-based drug major is recalling 571 vials of an injection used to relax muscles. Princeton-based Dr Reddy's Laboratories, Inc is recalling the affected lot of Succinylcholine Chloride Injection due to "Out-of-Specification result during the six-month stability testing," the USFDA stated. The company initiated the nationwide (US) Class II recall on September 26 this year. The USFDA stated that US-based arm of Zydus Lifesciences is recalling over 1,500 boxes of an antiviral medication used primarily to treat chronic hepatitis B virus. Pennington, New Jersey-based Zydus Pharmaceuticals (USA) Inc is recalling 912 and 600 bottles of Entecavir tablets in strengths of 0.5 mg and 1 mg respectively due to "failed .

One shot every six months: India could change HIV prevention forever

A long-acting HIV jab promises near-perfect protection at just $40 a year, but 115 nations must wait for India's approval of generic production

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Dr Reddy's and Hetero to sell generic HIV prevention drug for $40 a year

The price tag, which will enable much broader access in low-and middle-income countries, compares with an estimated US price of around $28,000 a year for branded Yeztugo

Pharma in bitter health: Stocks sink upto 38% in 2025; time to bottom fish?

Among stocks, Natco Pharma plunged 37.85%, Ipca Labs 22.43%, Aurobindo Pharma 17.99%, and Sun Pharma 14.30%. Other laggards include Lupin (13.25%), and Dr Reddy's (5.17%).

Dr Reddy's signs pact with J&J to acquire vertigo treatment brand

Dr Reddy's Laboratories on Thursday announced the completion of a definitive transaction with Johnson & Johnson to acquire Stugeron brand across the EMEA regions, with India and Vietnam as key markets. Stugeron contains Cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo. The acquisition presents a strategic opportunity for the Hyderabad-based drug firm to expand its footprint in the anti-vertigo space as well as strengthen its Central Nervous System (CNS) portfolio, Dr Reddy's Laboratories said in a statement. Dr Reddy's acquisition of the brand reflects a steady advancement in the company's efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of CNS portfolio, said MV Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy's Laboratories. "Backed by our strong market access, we intend to extend the reach of Stugeron and its associated products across 18 key markets in the ..

Stocks to watch today, Sep 11: Bajaj Finserv, DRL, Mazagon, Jupiter Wagons

Stocks to watch on Thursday, September 11: Keystone Realtors, RVNL, Deepak Fertilisers, Torrent Pharma and Adani Ports are among top stocks to track today.

Dr Reddy's hopes GST reforms will fix pharma tax issues, boost access

Dr Reddy's Laboratories on Tuesday expressed hope that the new GST structure will take care of existing challenges and aid in ushering a rationalised, industry-friendly tax framework for the pharmaceutical industry. For an extended period, the pharmaceutical sector has faced structural challenges, including higher GST rates and an inverted duty structure, which have impacted the cost efficiency of domestic manufacturing and the affordability of medicines, Dr Reddy's Laboratories Chairman Satish Reddy said in a statement. "We are optimistic that the forthcoming reforms will address these critical concerns and introduce a rationalised, industry-friendly tax framework," he noted. Such measures will significantly improve the affordability and accessibility of essential medicines for every citizen, while also enhancing the global competitiveness and innovation capacity of the Indian pharmaceutical industry, Reddy said. The industry remains fully committed to working in close partnership

Dr Reddy's launches novel drug for chronic constipation management

Dr Reddy's Laboratories on Tuesday said it has launched a first-in-class generic medication for chronic constipation in the country. The drug firm has launched Linaclotide, a first-in-class guanylate cyclase-C (GC-C), under the brand name Colozo. Linaclotide is a USFDA-approved medication indicated for adults suffering from chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C) in adults, and functional constipation (FC) in paediatric patients aged 6 to 17 years. "The launch of Colozo marks a significant step in our gastrointestinal segment in India and adds to our list of novel and first-in-class drugs after the launch of BixiBat in India last year," Dr Reddy's CEO Branded Markets (India and Emerging Markets) MV Ramana said in a statement. With Colozo, the company continues to strengthen its commitment to deliver advanced therapies that meaningfully improve everyday patient care, in keeping with the goal to serve 1.5 bn patients by 2030, he ...

Dr Reddy's Labs, Lupin: Nifty Pharma slips 2% amid Trump tariff jitters

Nifty Pharma index declined 1.5 per cent in trade after US President Donald Trump warned to impose a 25 per cent tariff on Indian goods starting August 1

Sun Pharma, Lupin, Dr Reddy's recall products in US due to mfg issues

Domestic drug majors Sun Pharma, Lupin and Dr Reddy's Laboratories are recalling drugs in the US market due to manufacturing issues and product mix up, according to the US health regulator. As per the latest Enforcement Report of US Food and Drug Administration (USFDA), the Mumbai-headquartered Sun Pharmaceutical Industries is recalling 5,448 bottles of a generic medication in the US. Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules (60 mg) due to "Failed Dissolution Specifications", the US health regulator stated. The medication is used to treat attention deficit hyperactivity disorder (ADHD). The drug firm initiated the Class II recall in the US on June 16 this year, it added. Another Mumbai-based drug maker Lupin is recalling 58,968 bottles of a generic combination medication used to treat high blood pressure. Naples-based Lupin Pharmaceuticals Inc is recalling Lisinopril and Hydrochlorothiazide tablets (US

Q1 miss for Dr Reddy's, but analysts remain hopeful for future prospects

Despite missing Q1 expectations, Dr Reddy's continues to see growth in key markets like Europe and India, while managing costs to offset challenges in the US

How to trade Dr Reddys, Tata Consumer, Bajaj Housing post Q1 results?

Technical charts hint at a likely positive bias for Dr Reddy's stock, while a negative outlook for Tata Consumer. Bajaj Housing Finance is likely to remain range-bound.

Dr Reddy's Laboratories Q1 print misses target; brokerages split on outlook

Dr Reddy's Laboratories' posted a revenue of ₹8,545.2 crore, up 11 per cent year-on-year (Y-o-Y) but flat sequentially.

Stocks to Watch today, July 24: Infosys, Dr Reddy's, Coforge, Tata Consumer

Stocks to Watch today, July 24, 2025: Infosys, IndusInd Bank, BEML and Bajaj Housing Finance are some of the top stocks to watch today.

Dr Reddy's Q1 profit up 1% to ₹1,410 crore, revenue rises to ₹8,545 cr

Dr Reddy's Laboratories on Wednesday reported a 1 per cent increase in consolidated net profit to Rs 1,410 crore during the Juen quarter. The Hyderabad-based drug major reported a net profit of Rs 1,392 crore in the year-ago period. Revenue increased to Rs 8,545 crore in he period under review from Rs 7,673 crore a year earlier. "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio," Dr Reddy's Co-Chairman & MD G V Prasad said. The pricing pressure on Lenalidomide is expected to intensify in the US generics market, he noted. "We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad said. Shares of the company ended 0.58 per cent up at Rs 1,247.55 apiece on the BSE.

Q1 results today: Infosys, Dr. Reddys Lab, Bajaj Housing among 60 companies

Q1 FY26 company results: Mahindra Holidays & Resorts, Aditya Birla Real Estate, Tata Consumer Products, and Bajaj Steel will also release their April-June quarter earnings reports today

Dr Reddy's gets 7 USFDA observations after Srikakulam plant inspection

A Form 483 is issued by the US health regulator when inspectors identify conditions that may violate the Food, Drug, and Cosmetic (FD&C) Act or relevant guidelines

Dr Reddy's expects US sales dip in FY26, aims for resilience via scale-up

With increased US competition from FY26, DRL plans portfolio shifts, inorganic growth, cost control and global expansion to manage profit and revenue impact